Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.

Mark N Stein,Armelle Vinceneux,Debbie Robbrecht,Bernard Doger,Karen A Autio,Michael T Schweizer,Emiliano Calvo, Laura Medina, Marloes Van Dongen, Jean-Laurent Deville, Alice Bernard-Tessier, Debopriya Ghosh, Kristin Shotts, Fei Shen,Pharavee Jaiprasart, Ruchi Chaudhary, Shujian Wu, Leanne Cartee, Robert Schnepp, Daria Gaut, Josh Lauring, Sherry C Wang, Victor M Villalobos,Capucine Baldini

Journal of clinical oncology official journal of the American Society of Clinical Oncology（2025）

Cited 0|Views1

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined